MDXG (MDXG) revenue breakdown
By segment, Wound & Surgical is the largest at 94% of fiscal 2021 revenue, growing 12% a year over 1 years.
By product, Wound is the largest at 66% of fiscal 2025 revenue, growing 16% a year over 2 years.
Revenue by segment
Fiscal years, as MDXG reports them in its 10-K filings; fiscal 2021 total $256M.
| Segments | 2020 | 2021 | Share |
|---|---|---|---|
| Wound & Surgical | $213M | $239M | 94% |
| Regenerative Medicine | $32M | $17M | 6% |
Revenue by product
Fiscal years, as MDXG reports them in its 10-K filings; fiscal 2025 total $419M.
| Products | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Wound | — | — | — | $206M | $231M | $276M | 66% |
| Surgical | — | — | — | $116M | $118M | $142M | 34% |
| Tissue/Other | $193M | — | — | — | — | — | — |
| Hospital | — | $142M | $163M | — | — | — | — |
| Private Office | — | $75M | $77M | — | — | — | — |
| Section 351 | $32M | — | — | — | — | — | — |
| Other | $8M | $25M | $27M | — | — | — | — |
| Cord | $16M | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for MDXG.
Open MDXG in InvestinglyQuestions
Where does MDXG make its money?
In fiscal 2021, by segment: Wound & Surgical $239M, Regenerative Medicine $17M.
From MDXG's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.